All News

RNL22 RA Best Management

RNL 2022: Rheumatoid Arthritis - Best Management

Jack Cush, MD

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Read Article
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Read Article
cardiac2.jpg (keep)

Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease

Jack Cush, MD

The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.

Read Article
Long,covid

Long COVID Manifestations

MMWR

The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome.  Long COVID appears to affect up to 20% of those who survive COVID-19 infection. 

Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

Jack Cush, MD

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Read Article
#OP0251 #EULAR2022 Any data to support association of RA-ILD with poor #COVID outcomes? A study is US >500 pts (9% ILD) showed ILD as well as poor RA status (RF+ & erosion) increased risk. Detailed analysis inc Radiographic + PFT cd help stratify risk further @RheumNow https://t.co/E89dd38GQS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
CTD associated ILD 🫁: lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc- ILD and RA-ILD vs. non ILD patients with AUC 0.79. As many lncRNA, unknown if biomarker only or has a pathogenic role. @RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD
Aurelie Najm AurelieRheumo ( View Tweet)
Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk
Richard Conway RichardPAConway ( View Tweet)
Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
Richard Conway RichardPAConway ( View Tweet)
Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5

Links:

Richard Conway RichardPAConway ( View Tweet)
RABBIT registry data on CV events with JAKi. Incidence rate low 0.41/100PY. No increase compared to TNFi RR 0.94 (0.39-2.38). No increase in high-risk group RR 0.90 (0.37-2.17). Reassuring with wide CI's. @RheumNow #EULAR2022 OP0135 https://t.co/vBSsnfeBoR https://t.co/iYDZsNwMye

Links:

Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0136: PROTECT-RA Cohort - 150 pts established RA Cholesterol loading capacity (CLC) on macrophages ⭐️High CLC correlates with CV events ⭐️bDMARD use affects CLC @RheumNow https://t.co/9ngaH9yUI7
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 OP0071 Association between long-term exposure to air pollution (fine particulate matter) and immune-mediated disease in Italy ⭐️⬆️ risk of autoimmune disease, esp RA as well as CTD, IBD ⭐️Every 10 ug/m3 increase in PM, associated with incremental 7% risk @RheumNow https://t.co/x57CXUHSHb
Eric Dein ericdeinmd ( View Tweet)
Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.

Janet Pope Janetbirdope ( View Tweet)

#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increaseing negative associations w/ NAFLD severity (mild OR 0.392; Mod: 0.379; Severe 0.148). NAFLD negatively assoc w/ CKD risk in gout https://t.co/5fuIiO1LwM https://t.co/Jp8CjWkn5m

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 100 pts w/ gouty arthritis, 51% had hypertension, nearly half insufficiently controlled. Undiagnosed HTN was seen in 18%. Gouty pts w/ HTN frequently (92%) had serum uric acid levels above the target https://t.co/jc0UGyrK2B https://t.co/kDD2KfQd3K

Links:

Dr. John Cush RheumNow ( View Tweet)
86 #SLE pts w/ pulmonary embolism (age 38 yrs; avg lupus duration 46.5 mos) found 20% died; 1 yr (83.4%) & 3-year survival (79.4%). Mortality Predictors = Thrombocytopenia & lymphocytopenia. HCQ & anticoagulation were protective https://t.co/ot7H6LeLmu https://t.co/WdPgvOF8jJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Countdown to Step 2, each week I'll be posting one of my favorite doodles from studying! This week- Pulmonary Arterial Hypertension #Meddoodles https://t.co/Hj1i87zZbA
Sarah Lyon sarahthelyon ( View Tweet)
Data from Scleroderma Lung Study (CTX vs MMF in PSS) shows that early progression of ILD by CXR scoring (≥ 2% at 12 or 24 months) experienced significantly worse long-term survival than those with stable Xrays (P = .014). https://t.co/hv2WNJ4Chr https://t.co/W5RIhoIGtT

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×